Home

Cytokinetics, Incorporated - Common Stock (CYTK)

37.35
-5.57 (-12.98%)
NASDAQ · Last Trade: May 2nd, 7:29 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · May 2, 2025
Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
The DJS Law Group announces that it is investigating claims on behalf of investors of Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of the securities laws.
By DJS Law Group · Via Business Wire · May 2, 2025
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?
Via MarketBeat · September 25, 2024
Cytokinetics Inc. (NASDAQ: CYTK) Leading the Way in Thursday Trading Based on Percentage Gain
Cytokinetics, Incorporated (NASDAQ: CYTK) is one of today’s top gainers. The company’s shares have moved 1.2% on the day to $32.12.
Via Investor Brand Network · December 21, 2023
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It includes many rare neurological disease disorders like Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis. It is also associated with aging and Traumatic brain injury. According to […]
Via FinancialNewsMedia · June 22, 2022
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we discuss the FDA’s Orphan Drug Designation program in reference to AbbVie (NYSE: ABBV), Crispr Therapeutics AG (NASDAQ: CRSP), Cytokinetics, Inc. (NASDAQ: CYTK), and […]
Via FinancialNewsMedia · May 18, 2022